Clinical Report: Correction on Editorial Review of Epigenomics and Metabolomics

Overview

This report addresses the corrections made to the affiliations of authors in the editorial on epigenomics and metabolomics in breast cancer.

Background

This correction ensures proper attribution of authorship and institutional affiliations in the ongoing discourse surrounding these topics.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

• Correction of author affiliations for Parmod Kumar and Anupama Modi.
• Parmod Kumar's correct affiliation is now listed as Department of Medical Oncology Hematology, All India Institute of Medical Sciences Jodhpur.
• Anupama Modi's correct affiliation is now listed as GTU-School of Applied Science and Technology, Ahemdabad, India.
• Previous erroneous affiliations have been removed to reflect accurate institutional associations.
• The original editorial has been updated to include these corrections.

Clinical Implications

Accurate author attribution is essential for maintaining the integrity of scientific literature. This correction emphasizes the importance of proper institutional representation in research publications.

Conclusion

The corrections made to the affiliations of the authors enhance the clarity and credibility of the editorial on epigenomics and metabolomics in breast cancer.

Related Resources & Content

1. Purohit P, Kumar P, Modi A, Frontiers in Oncology, 2026 -- Editorial: Epigenomics and metabolomics: pioneering new frontiers in breast cancer research and treatment
2. Frontiers in Oncology — Editorial: Epigenetic modulation in cancer
3. Frontiers in Endocrinology — Editorial: Changes in Metabolic Characteristics Associated with Gastrointestinal Tract Cancers, Volume II
4. Frontiers in Oncology — Editorial: Exploring molecular mechanisms in cancer through tumor molecular pathology
5. Frontiers in Medicine — Editorial: Biomarkers in head and neck cancer: genomic insights and nuclear medicine innovations
6. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up‡ - PubMed
7. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group | Medicines Awareness Service
8. DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches | Journal of Translational Medicine | Springer Nature Link